<p>Skye Bioscience Inc., a clinical-stage biotechnology company focused on metabolic health, has announced the ongoing Phase 2a clinical trial of nimacimab, a peripherally-restricted CB1 inhibitor antibody, in obesity (ClinicalTrials.gov: NCT06577090). The study is also evaluating the combination of nimacimab with a GLP-1R agonist (Wegovy®). Additionally, Skye presented preclinical results at the Keystone Obesity Therapeutics conference, highlighting the efficacy of nimacimab alone, in combination with tirzepatide, and as a maintenance therapy post tirzepatide discontinuation in a diet-induced obesity mouse model. Results from this preclinical work were presented at the conference; clinical trial results have not yet been announced. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9644919) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Skye Bioscience Launches Phase 2a Trial of Nimacimab for Obesity Treatment